A lab research article examining a proposed two-step immunotherapy strategy that uses CAR T cell–driven inflammation to prime tumors for follow-up TCR-engineered T cell attack, offering insight into rationale and experimental approaches.
Key Takeaways
- You have multiple emails registered with Frontiers: You don't have a Frontiers account ?
- Chimeric antigen receptor (CAR) T cell effector function, including IFNγ production, is MHC class I-independent
- Aim: We aimed to enhance neuroblastoma immunotherapy by combining CAR- and TCR-engineered T cells